Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
-- State-of-the-art neoantigen prediction platform now predicts HLA Class I presentation of epitopes with
Stay updated with breaking news from Karin Jooss. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- State-of-the-art neoantigen prediction platform now predicts HLA Class I presentation of epitopes with
/PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief executive officer Hans...
-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody responses that persist for at least 6 months, including variant cross-reactive nAb, in previously unvaccinated ... | April 17, 2023
Operator: Greetings. My name is Joe and I'll be your conference operator today. Welcome to Gritstone bio's, Fourth Quarter and Full Year 2022 Results Conference Call.
Neoantigen vaccine candidate, SLATE-KRAS has demonstrated early evidence of efficacy - News - PharmaTimes